Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer

Basit Öğe Kaydı
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKanbay, Mehmet
dc.contributor.authorSolak, Yalçın
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKanıtez, Metin
dc.contributor.authorBalık, Emre
dc.contributor.authorMandel, Nil Molinas
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:27Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:27Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000385182500005
dc.descriptionPubMed ID: 26781472
dc.description.abstractBevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.
dc.identifier.citationSelçukbiricik, F., Kanbay, M., Solak, Y., Bilici, A., Kanıtez, M., Balık, E. ... Mandel, N. M. (2016). Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer. Clinical & Translational Oncology, 18(11), 1082-1087. https://dx.doi.org/10.1007/s12094-016-1485-1
dc.identifier.doi10.1007/s12094-016-1485-1
dc.identifier.endpage1087
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue11
dc.identifier.scopusqualityQ2
dc.identifier.startpage1082
dc.identifier.urihttps://dx.doi.org/10.1007/s12094-016-1485-1
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2218
dc.identifier.volume18
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofClinical & Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBevacizumab
dc.subjectUric Acid
dc.subjectHypoxia
dc.subjectMetastatic Colorectal Cancer
dc.subjectCarcinoembryonic Antigen
dc.subjectSurvival
dc.titleSerum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici, Ahmet.pdf
Boyut:
434.83 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu